STOCK TITAN
  1. Home
  2. Sec-filings
  3. GLPGF
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront (NASDAQ: LKFT) executes €1.9M share repurchase tranche

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics reported progress under its previously announced share repurchase program, buying back 77,667 ordinary shares between 15 and 19 June 2026. The company paid an average of €24.6586 per share, for a total consideration of €1,915,162.13 across Euronext trades during this period.

After these transactions, Lakefront held 116,204 of its own ordinary shares as of market close on 19 June 2026. The company reiterates that repurchases form part of its capital management strategy, while also reminding investors that any plans to repurchase shares involve forward-looking statements and are subject to various risks and uncertainties described in its SEC filings.

Positive

  • None.

Negative

  • None.
Shares repurchased 77,667 shares Repurchased between 15 and 19 June 2026
Average repurchase price €24.6586 per share Weighted average over 77,667 shares
Total repurchase amount €1,915,162.13 Cost of shares bought 15–19 June 2026
Shares bought 15 June 2026 13,272 shares EXNT at average €24.9331
Shares bought 19 June 2026 17,430 shares EXNT at average €24.5966
Treasury shares held 116,204 shares Own shares held as of 19 June 2026 close
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
regulated information regulatory
"Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
ordinary shares financial
"statements regarding Lakefront’s plans to repurchase its ordinary shares"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Lakefront Biotherapeutics (LKFT) announce in the June 2026 Form 6-K?
Lakefront Biotherapeutics reported buying back 77,667 ordinary shares under its repurchase program between 15 and 19 June 2026. The purchases were executed on Euronext and are part of the company’s broader capital management approach.

How many Lakefront Biotherapeutics (LKFT) shares were repurchased and at what cost?
Lakefront repurchased 77,667 ordinary shares for a total of €1,915,162.13. The average price paid was €24.6586 per share, with individual daily trades executed in a narrow price range on Euronext.

Over what period did Lakefront Biotherapeutics (LKFT) conduct the reported share repurchases?
The company repurchased shares between 15 June 2026 and 19 June 2026. During these five trading days, it executed multiple transactions on Euronext under its previously announced share repurchase program.

How many treasury shares does Lakefront Biotherapeutics (LKFT) now hold?
As of market close on 19 June 2026, Lakefront held 116,204 of its own ordinary shares. This figure reflects the cumulative impact of buybacks completed under its ongoing repurchase program up to that date.

On which market did Lakefront Biotherapeutics (LKFT) execute these share repurchases?
All reported share repurchases were executed on Euronext, identified as EXNT in the transaction table. The company’s ordinary shares are listed on both Euronext and NASDAQ, but this specific disclosure covers trades on Euronext only.

Does Lakefront Biotherapeutics (LKFT) treat its repurchase plans as forward-looking statements?
Yes. The company states that plans to repurchase its ordinary shares are forward-looking statements. It cautions that such plans involve risks and uncertainties described in its Form 20-F and subsequent SEC filings.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On June 23, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated June 23, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: June 24, 2026     /s/ Annelies Denecker    
  Annelies Denecker
  Company Secretary
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 77,667 Lakefront shares between 15 June 2026 and 19 June 2026, as follows:

Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
15/06/2026 EXNT 13,272 24.9331 330,912.10 24.7200 25.2200
16/06/2026 EXNT 16,400 24.5495 402,611.80 24.1200 25.2600
17/06/2026 EXNT 13,605 24.4212 332,250.43 24.0000 24.7800
18/06/2026 EXNT 16,960 24.8036 420,669.06 24.4800 25.1200
19/06/2026 EXNT 17,430 24.5966 428,718.74 24.3600 24.7600
Total   77,667 24.6586

 		 1,915,162.13

 		 24.3360 25.0280

As of market close on 19 June 2026, Lakefront holds 116,204 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases